BioLineRx Research and Development Expenses 2012-2024 | BLRX

BioLineRx research and development expenses from 2012 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

BioLineRx Research and Development Expenses 2012-2024 | BLRX

BioLineRx research and development expenses from 2012 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.8B
Takeda Pharmaceutical (TAK)$43.8B
Merck (MKKGY)$21B
Astellas Pharma (ALPMY)$20.2B
Sandoz Group AG (SDZNY)$19.8B
United Therapeutics (UTHR)$18.3B
Summit Therapeutics (SMMT)$15.8B
Neurocrine Biosciences (NBIX)$12.7B
Shionogi (SGIOY)$12.5B
Catalent (CTLT)$10.8B
Madrigal Pharmaceuticals (MDGL)$7.6B
Jazz Pharmaceuticals (JAZZ)$7.6B
Orion OYJ (ORINY)$6.8B
Corcept Therapeutics (CORT)$6.2B
Ionis Pharmaceuticals (IONS)$6.2B
Crinetics Pharmaceuticals (CRNX)$4.9B
PTC Therapeutics (PTCT)$3.4B
Dyne Therapeutics (DYN)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.9B
Arrowhead Pharmaceuticals (ARWR)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Soleno Therapeutics (SLNO)$2.5B
NewAmsterdam Pharma (NAMS)$2.2B
Recursion Pharmaceuticals (RXRX)$2B
Centessa Pharmaceuticals (CNTA)$1.9B
Harrow (HROW)$1.9B
Ocular Therapeutix (OCUL)$1.7B
Xencor (XNCR)$1.7B
ARS Pharmaceuticals (SPRY)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.6B